Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national blog main
national top stories
10
×
life sciences
biotech
boston blog main
boston top stories
san francisco blog main
san francisco top stories
national
san diego blog main
san diego top stories
startups
deals
detroit blog main
detroit top stories
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
cancer
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
crispr therapeutics
merck
pfizer
president trump
roche
vc
abbvie
albert bourla
bristol-myers squibb
cancer immunotherapy
What
today
10
×
drug
new
cancer
crispr
future
medical
annual
based
big
bio
biotech
cas
clinical
oncology
potential
roundup
society
startup
technology
accelerating
acquisitions
advance
ahead
aiming
albert
ambien
ambys
american
ann
announced
approval
arbor
asco
attend
attendees
attention
available
away
biggest
Language
unset
unknown
Current search:
today
×
" national top stories "
×
@xconomy.com
4 years ago
Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
After Scoring New Capital, Fifth Eye Prepares to Seek FDA Approval
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs